Recruiting PHASE1 INTERVENTIONAL 2-arm NCT06857214

A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus

A Randomized Controlled Phase I Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GNC-038 Tetra-specific Antibody Injection in Systemic Lupus Erythematosus

Sponsor: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Conditions Systemic Lupus Erythematosus

Interventions GNC-038 Placebo

Updated 2 times since 2025 Last updated: Jun 23, 2025 Started: Jun 4, 2025 Primary completion: Dec 31, 2027 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Systemic Lupus Erythematosus and is currently actively recruiting participants. Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

2 versions recorded

Jul 2025 — Present [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Apr 2025 — Jul 2025 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Sichuan Baili Pharmaceutical Co., Ltd.

Data source: Sichuan Baili Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China